Focused On-demand Library for Regulator of nonsense transcripts 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q92900

UPID:
RENT1_HUMAN

ALTERNATIVE NAMES:
ATP-dependent helicase RENT1; Nonsense mRNA reducing factor 1; Up-frameshift suppressor 1 homolog

ALTERNATIVE UPACC:
Q92900; O00239; O43343; Q86Z25; Q92842

BACKGROUND:
The protein Regulator of nonsense transcripts 1, also recognized as ATP-dependent helicase RENT1, serves as a critical component in the nonsense-mediated mRNA decay pathway. By engaging in the recognition and elimination of faulty mRNAs containing premature termination codons, UPF1 ensures the fidelity of gene expression. Its function extends beyond NMD, influencing the degradation of replication-dependent histone mRNA and potentially modulating the stability of normal transcripts.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Regulator of nonsense transcripts 1 offers promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8390 of 8789